• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Alpha Cognition Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    4/14/26 4:00:32 PM ET
    $ACOG
    Get the next $ACOG alert in real time by email
    false 0001655923 A1 00-0000000 0001655923 2026-04-10 2026-04-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    Current Report

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): April 10, 2026

     

    Alpha Cognition Inc.

    (Exact name of registrant as specified in its charter)

     

    British Columbia  

    001-42403

      N/A
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification Number)

     

    1452 Hughes Rd., Ste 200
    Grapevine, Texas
      76051
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: 858-344-4375

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class:   Trading Symbol   Name of each exchange on which registered:
    Common Shares, no par value   ACOG   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On April 10, 2026, Alpha Cognition Inc. (the “Company”) entered into a settlement agreement and mutual release (the “Early Settlement Agreement”) with Galantos Pharma GmbH i.L. a company in liquidation and incorporated under the laws of the Federal Republic of Germany (“Galantos”), to extinguish certain future payment obligations arising under the Memogain Asset Purchase Agreement dated August 23, 2013 (the “Original Agreement”) by and between Galantos and Neurodyn Life Sciences Inc., as assumed by the Company pursuant to that certain Memogain Technology License Agreement by and between Neurodyn and Neurodyn Cognition Inc. dated as of October 18, 2013, as amended by that certain Second Amended Memogain Technology License Agreement by and among Neurodyn, Alpha Cognition Canada Inc. and Alpha dated as of March 1, 2023 (as amended, the “License Agreement”).

     

    Pursuant to the Early Settlement Agreement, the Company agreed to make a one-time payment to the Galantos of EUR 5,214,220 in full satisfaction of remaining contingent obligations, including royalty and milestone-related payments under the Original Agreement. Further, in consideration of the one-time payment, Galantos has agreed to waive and release the Company and its related parties for any causes of actions arising from the Original Agreement. The settlement amount represents an approximate 40% discount to the estimated market value of the remaining obligations, based on management’s assessment of projected future payments and comparable market benchmarks.

     

    The foregoing description of the Early Settlement Agreement is qualified in its entirety by reference to the full text of the Early Settlement Agreement, which is filed as Exhibit 10.1 to this report and is incorporated by reference herein.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit
    No.
      Description
    10.1   Settlement Agreement and Mutual Release with Galantos dated April 10, 2026
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      ALPHA COGNITION INC.
       
      By: /s/ Michael McFadden
        Michael McFadden
        Chief Executive Officer
    Dated: April 14, 2026  

     

     

    2

     

    Get the next $ACOG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOG

    DatePrice TargetRatingAnalyst
    5/29/2026$12.00Buy
    Maxim Group
    4/17/2026$14.00Buy
    Craig Hallum
    3/18/2025$20.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACOG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Alpha Cognition with a new price target

    Maxim Group initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $12.00

    5/29/26 7:48:09 AM ET
    $ACOG

    Craig Hallum initiated coverage on Alpha Cognition with a new price target

    Craig Hallum initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $14.00

    4/17/26 8:03:30 AM ET
    $ACOG

    H.C. Wainwright initiated coverage on Alpha Cognition with a new price target

    H.C. Wainwright initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $20.00

    3/18/25 7:48:36 AM ET
    $ACOG

    $ACOG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Opaleye Management Inc. bought $434,714 worth of shares (73,738 units at $5.90) (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    5/29/26 7:21:38 PM ET
    $ACOG

    Large owner Opaleye Management Inc. bought $140,545 worth of shares (24,376 units at $5.77) (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    5/22/26 4:05:27 PM ET
    $ACOG

    Chief Operating Officer D'Angelo Lauren bought $20,160 worth of shares (3,500 units at $5.76), increasing direct ownership by 3% to 140,695 units (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    5/19/26 5:02:16 PM ET
    $ACOG

    $ACOG
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Alpha Cognition Inc.

    SCHEDULE 13G/A - Alpha Cognition Inc. (0001655923) (Subject)

    5/22/26 4:05:20 PM ET
    $ACOG

    SEC Form 10-Q filed by Alpha Cognition Inc.

    10-Q - Alpha Cognition Inc. (0001655923) (Filer)

    5/14/26 4:01:44 PM ET
    $ACOG

    Amendment: SEC Form SCHEDULE 13G/A filed by Alpha Cognition Inc.

    SCHEDULE 13G/A - Alpha Cognition Inc. (0001655923) (Subject)

    5/12/26 7:11:10 PM ET
    $ACOG

    $ACOG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Opaleye Management Inc. bought $434,714 worth of shares (73,738 units at $5.90) (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    5/29/26 7:21:38 PM ET
    $ACOG

    Large owner Opaleye Management Inc. bought $140,545 worth of shares (24,376 units at $5.77) (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    5/22/26 4:05:27 PM ET
    $ACOG

    Chief Operating Officer D'Angelo Lauren bought $20,160 worth of shares (3,500 units at $5.76), increasing direct ownership by 3% to 140,695 units (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    5/19/26 5:02:16 PM ET
    $ACOG

    $ACOG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update

    ZUNVEYL generated net product revenue of $3.5 million in Q1 2026, a 40% quarter-over-quarter increase Cumulative net product revenue totaled $10.3 million through first four full quarters of launch Q1 2026 bottles dispensed increased 23% quarter-over-quarter to 6,054, with March representing the strongest month of demand since launch Approximately 75% of prescribers and 81% of facilities demonstrated repeat utilization, reinforcing durable adoption trends Real-world clinical studies active, with BEACON enrolling ahead of schedule Cash and cash equivalents totaled $54 million as of March 31, 2026, supporting the Company's continued target of operating profitability in 2027 Compan

    5/14/26 4:15:00 PM ET
    $ACOG

    Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

    Management to host conference call on Thursday, May 14, 2026 at 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, May 14, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its first quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website at www.alphacognition.com/investors/news/. Following the release, management

    4/28/26 4:30:00 PM ET
    $ACOG

    Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences

    Alpha Cognition, Inc. (NASDAQ:ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that Michael McFadden, Chief Executive Officer, will participate in three investor conferences in May. Event details are as follows: Market Movers Investor Summit Format: Presentation and 1x1 meetings Date/Time: Tuesday, May 5 at 2:40 p.m. ET H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq Format: Fireside Chat and 1x1 meetings Date/Time: Tuesday, May 19 at 4:30 p.m. ET Craig Hallum's 23rd Annual Institutional Investor Conference Format: 1x1 meetings Date: May 28,

    4/27/26 8:00:00 AM ET
    $ACOG

    $ACOG
    Leadership Updates

    Live Leadership Updates

    View All

    Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

    Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Bethany Sensenig to its Board of Directors, effective April 15, 2026. Ms. Sensenig brings decades of leadership experience across the pharmaceutical and biotechnology industries, with deep expertise in finance, corporate strategy, and operations. "On behalf of the entire Board of Directors, it is a pleasure to welcome Bethany Sensenig, a highly accomplished industry leader," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc. "Her broad experience acro

    4/20/26 5:00:00 PM ET
    $ACOG
    $KALV
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

    Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

    4/10/25 8:30:00 AM ET
    $ACOG
    $CBAY
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

    Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; Rommel Fernandez, Vice President of Corporate Strategy and Operations; and Kurt Grady, Vice President of Medical Affairs. These hires mark significant milestones in building Alpha Cognition's commercial and medical teams as the company prepares for the upcoming launch of ZUNVEYL, its innovative treatment for mild to moderate Alzheimer's disease. Ms. Pesa brings 25 years of pharmaceutic

    1/14/25 8:30:00 AM ET
    $ACOG

    $ACOG
    Financials

    Live finance-specific insights

    View All

    Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update

    ZUNVEYL generated net product revenue of $3.5 million in Q1 2026, a 40% quarter-over-quarter increase Cumulative net product revenue totaled $10.3 million through first four full quarters of launch Q1 2026 bottles dispensed increased 23% quarter-over-quarter to 6,054, with March representing the strongest month of demand since launch Approximately 75% of prescribers and 81% of facilities demonstrated repeat utilization, reinforcing durable adoption trends Real-world clinical studies active, with BEACON enrolling ahead of schedule Cash and cash equivalents totaled $54 million as of March 31, 2026, supporting the Company's continued target of operating profitability in 2027 Compan

    5/14/26 4:15:00 PM ET
    $ACOG

    Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

    Management to host conference call on Thursday, May 14, 2026 at 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, May 14, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its first quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website at www.alphacognition.com/investors/news/. Following the release, management

    4/28/26 4:30:00 PM ET
    $ACOG

    Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update

    Alpha Cognition generated fourth quarter 2025 ZUNVEYL net product revenue of $2.5 million, contributing to full year 2025 total revenue of $10.2 million Fourth quarter bottles dispensed increased 62% quarter-over-quarter to 4,941, with December representing the strongest month since launch Executed second national PBM contract and initiating three studies to further support ZUNVEYL's positioning in long-term care Alzheimer's patients Cash and cash equivalents totaled $66 million at year-end 2025, supporting the company's continued target of operating profitability in 2027 Company to host conference call and webcast today, March 26, at 4:30 p.m. ET Alpha Cognition Inc. (ACOG: NASDA

    3/26/26 4:01:00 PM ET
    $ACOG